The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall ...

Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...

Barrington Research restated their outperform rating on shares of Dolby Laboratories (NYSE:DLB – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $100.00 ...

In the bond market, the yield on the benchmark 10-year U.S. Treasury note is at 4.523%, down -0.57%. The Euro Stoxx 50 Index is up +0.67% this morning as strong quarterly results from chip equipment ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...